Rotavirus Infections Clinical Trial
Official title:
A Phase II Randomized, Double Blind, Parallel Group Dose-ranging Study of Oral RV3-BB Rotavirus Vaccine Administered at a High, Mid and Low Titre as a 3 Dose Neonate Schedule or Administered at a High Titre as a 3 Dose Infant Schedule.
The purpose of this study is to determine the serum IgA response of three dose levels of the oral RV3-BB vaccine when administered in a neonatal schedule or when administered as a high dose in an infant schedule.
The primary objective of this study is to assess the cumulative anti-rotavirus serum IgA response (defined as a ≥3 fold increase from baseline) 4 weeks after 3 doses of RV3-BB administered in a neonatal schedule at a High, Mid or low vaccine titre. In addition the cumulative anti-rotavirus serum IgA response (defined as a ≥3 fold increase from baseline) 4 weeks after 3 doses of RV3-BB administered in an infant schedule at a high dose of vaccine will be assessed along with cumulative vaccine take and components of vaccine take after 3 doses of RV3-BB administered in a neonatal or infant schedule. The safety and tolerability of RV3-BB when administered as an infant or as a neonatal schedule will be described. ;
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT02538211 -
The Role of the Intestinal Microbiome in Enteric and Systemic Vaccine Immune Responses
|
N/A | |
Completed |
NCT02220439 -
Does the Fecal Microbiome Influence Rotarix Immunogenicity
|
N/A | |
Withdrawn |
NCT00757926 -
Safety and Immunogenicity Study of the Recombinant Human Bovine Reassortant Rotavirus Vaccine in Healthy Indian Infants
|
Phase 1/Phase 2 | |
Not yet recruiting |
NCT00484952 -
Surveillance of Hospitalizations Due to Rotavirus Infections Among Children From Israel
|
N/A | |
Completed |
NCT00092443 -
Dose Confirmation Efficacy Study (V260-007)
|
Phase 3 | |
Terminated |
NCT01357174 -
ROTATEQ™ Post-Marketing Surveillance in the Philippines
|
N/A | |
Recruiting |
NCT01363726 -
Surveillance of Rotavirus Gastroenteritis in Children <5 Years
|
N/A | |
Completed |
NCT00130832 -
Concomitant Use and Staggered Use of Vaccine and Oral Poliovirus (OPV) in Healthy Infants (V260-014)(COMPLETED)
|
Phase 3 | |
Recruiting |
NCT06080906 -
Phase II Clinical Trial of the Inactivated Rotavirus Vaccine
|
Phase 2 | |
Recruiting |
NCT03313128 -
SaniVac Trial - Sanitation and Oral Rotavirus Vaccine Performance
|
||
Completed |
NCT02542462 -
Potential Mechanisms for Intussusception After Rotavirus Vaccine-Pilot Study
|
Phase 4 | |
Completed |
NCT00346892 -
To Evaluate 2 Doses of GSK Biologicals' Oral Live Attenuated Human HRV Vaccine Co-administered With Either OPV or IPV
|
Phase 2 | |
Not yet recruiting |
NCT05212935 -
A Surveillance Study on Timing and Coverage Of Rotavirus and MenB Vaccine Co-administration in Campania Region, Italy
|
||
Completed |
NCT00092456 -
Consistency Lots Vaccine Study (V260-009)
|
Phase 3 | |
Completed |
NCT00981669 -
Rotavirus Vaccine Produced by Butantan Institute
|
Phase 1 | |
Completed |
NCT05037435 -
Safety and Immunological Efficacy of the Pentavalent Rotavirus Vaccine - Rota-V-Aid™ (Live Attenuated Oral, Freeze-dried) at Healthy Adults Aged 18 to 45 Years.
|
Phase 3 | |
Completed |
NCT03870061 -
Evaluation of an Infant Immunization Encouragement Program in Nigeria
|
N/A | |
Active, not recruiting |
NCT05621655 -
Safety and Immunogenicity Study of Recombinant Trivalent Rotavirus Subunit Vaccine in Healthy Infants and Toddlers
|
Phase 2 | |
Completed |
NCT00280111 -
Safety and Immunogenicity Study of Live Attenuated Indian Rotavirus Vaccine Candidate Strains 116E and I321 in Infants
|
Phase 1 | |
Completed |
NCT00090233 -
Rotavirus Efficacy and Safety Trial (REST)(V260-006)
|
Phase 3 |